FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890884370> ?p ?o ?g. }

• W2890884370 endingPage "S178" @default.
• W2890884370 startingPage "S178" @default.
• W2890884370 abstract "Pulmonary lymphangitic carcinomatosis is a disease in which advanced malignant tumors spreads diffuse throughout the lungs along lymphatic vessels. The previous treatment methods of PLC have no special curative effect except standard chemotherapy and symptomatic support. This paper retrospectively analyzed 13 patients with advanced lung cancer of PLC treated by apatinib in our hospital in 2017, whose clinical symptoms and therapeutic effects are as follows: To summarize and analyze 13 cases of pulmonary lymphangitic carcinomatosis of my department , and evaluate the therapeutic effect of apatinib on pulmonary lymphangitic carcinomatosis, for the effective treatment of pulmonary lymphangitic carcinomatosis. 13 cases of pulmonary lymphangitic carcinomatosis treated by our department from June 2017 to June 2018 were retrospectively analyzed, all patients were treated with apatinib orally at a daily dose of 425 mg for 6 consecutive weeks. Its therapeutic effect was summarized and analyzed , and the progression-free survival period (PFS) and overall survival rate (OS) were followed up. CT imaging findings before and after the treatment was the main index, supplemented by tumor markers (CEA, CA - 125, CYFRA21-1), analysis of blood gas, the change of clinical symptom index, etc for the analysis of adverse drug reactions. The efficacy of 13 patients with pulmonary lymphangitic carcinomatosis was evaluated. Classification of the therapeutic effect included 6 patients (46.1%) of partially relieved (PR),3 patients (23.0%) of stable disease (SD),4 patients (30.7%) of progressive disease (PD). Objective response rate (CR+PR) was 46.1%. Disease control rate DCR(CR+PR+SD) was 69.2%. Progression-free survival (PFS) was 5.2 months. Overall survival OS was 10.2 months. The CT imaging features of part patients before and after treatment improved markedly, the differences of tumor markers CEA, ca-125, cyfra21-1 and blood gas analysis were statistically significant (P<0.05), Pleural effusion, dyspnea and other clinical symptoms have different degrees of relief. Adverse events were mainly high blood pressure (3/13), rash (4/13), hand-foot syndrome (6/13), mild proteinuria (2/13), and All are tolerable. Pulmonary lymphangitic carcinomatosis is a disease of lymphatic spread in the advanced malignant tumors, Apatinib not only has good curative effect, but also brings obvious survival benefits, and the incidence of adverse reactions is low and the patient is well tolerated. Apatinib has become the main treatment of PLC compared to the traditional treatment." @default.
• W2890884370 created "2018-09-27" @default.
• W2890884370 creator A5082443791 @default.
• W2890884370 date "2018-09-01" @default.
• W2890884370 modified "2023-09-26" @default.
• W2890884370 title "P46 Experience in the Treatment of 13 Cases of Pulmonary Lymphangitic Carcinomatosis with Apatinib" @default.
• W2890884370 doi "https://doi.org/10.1016/j.jtho.2018.07.085" @default.
• W2890884370 hasPublicationYear "2018" @default.
• W2890884370 type Work @default.
• W2890884370 sameAs 2890884370 @default.
• W2890884370 citedByCount "3" @default.
• W2890884370 countsByYear W28908843702019 @default.
• W2890884370 countsByYear W28908843702022 @default.
• W2890884370 crossrefType "journal-article" @default.
• W2890884370 hasAuthorship W2890884370A5082443791 @default.
• W2890884370 hasBestOaLocation W28908843701 @default.
• W2890884370 hasConcept C102652120 @default.
• W2890884370 hasConcept C121608353 @default.
• W2890884370 hasConcept C126322002 @default.
• W2890884370 hasConcept C141071460 @default.
• W2890884370 hasConcept C143998085 @default.
• W2890884370 hasConcept C197934379 @default.
• W2890884370 hasConcept C2778822529 @default.
• W2890884370 hasConcept C2779134260 @default.
• W2890884370 hasConcept C2780668389 @default.
• W2890884370 hasConcept C71924100 @default.
• W2890884370 hasConcept C90924648 @default.
• W2890884370 hasConceptScore W2890884370C102652120 @default.
• W2890884370 hasConceptScore W2890884370C121608353 @default.
• W2890884370 hasConceptScore W2890884370C126322002 @default.
• W2890884370 hasConceptScore W2890884370C141071460 @default.
• W2890884370 hasConceptScore W2890884370C143998085 @default.
• W2890884370 hasConceptScore W2890884370C197934379 @default.
• W2890884370 hasConceptScore W2890884370C2778822529 @default.
• W2890884370 hasConceptScore W2890884370C2779134260 @default.
• W2890884370 hasConceptScore W2890884370C2780668389 @default.
• W2890884370 hasConceptScore W2890884370C71924100 @default.
• W2890884370 hasConceptScore W2890884370C90924648 @default.
• W2890884370 hasIssue "9" @default.
• W2890884370 hasLocation W28908843701 @default.
• W2890884370 hasOpenAccess W2890884370 @default.
• W2890884370 hasPrimaryLocation W28908843701 @default.
• W2890884370 hasRelatedWork W2381160389 @default.
• W2890884370 hasRelatedWork W2772987978 @default.
• W2890884370 hasRelatedWork W2791249304 @default.
• W2890884370 hasRelatedWork W2982295426 @default.
• W2890884370 hasRelatedWork W2985220689 @default.
• W2890884370 hasRelatedWork W2995984529 @default.
• W2890884370 hasRelatedWork W3029070866 @default.
• W2890884370 hasRelatedWork W3099440781 @default.
• W2890884370 hasRelatedWork W3197516152 @default.
• W2890884370 hasRelatedWork W4283763477 @default.
• W2890884370 hasVolume "13" @default.
• W2890884370 isParatext "false" @default.
• W2890884370 isRetracted "false" @default.
• W2890884370 magId "2890884370" @default.
• W2890884370 workType "article" @default.